Advertisement

Topics

REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation

05:43 EST 24 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma The new indication expands the availabili...

Other Sources for this Article

Media:
Stacey Minton
Office: +41 32 729 62 36 / Cell: +41 79 265 23 52
sminton@celgene.com
or
Maryline Iva
+41 79 816 16 94
miva@celgene.com
or
Investors:
+41 32 729 8303
ir@celgene.com

NEXT ARTICLE

More From BioPortfolio on "REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...